Abstract
Edoxaban is the fourth non-vitamin K antagonist oral anticoagulant now available for clinical use in the prevention of stroke/systemic embolism in atrial fibrillation (AF) and in the treatment of venous thromboembolism (VTE), after the completion of large-scale randomized comparative clinical trials with the vitamin K antagonist warfarin. Edoxaban has some peculiar pharmacological properties and outcome data. Here a group of experts in AF and VTE answers a set of questions on its practical use, trying to define the profile of patients that would be most appropriate for its use.
Original language | English |
---|---|
Pages (from-to) | 1-18 |
Number of pages | 18 |
Journal | Advances in Therapy |
DOIs | |
Publication status | Accepted/In press - Feb 13 2017 |
Externally published | Yes |
Keywords
- Atrial fibrillation
- Edoxaban
- Non-vitamin K antagonist oral anticoagulants
- Oral anticoagulants
- Venous thromboembolism
- Vitamin K antagonists
ASJC Scopus subject areas
- Medicine(all)
- Pharmacology (medical)